TY - JOUR
T1 - Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
AU - Swords, Ronan
AU - Alvarado, Yesid
AU - Cortes, Jorge
AU - Giles, Francis J.
PY - 2007/4
Y1 - 2007/4
N2 - Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.
AB - Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR breakpoints. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=34248401176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248401176&partnerID=8YFLogxK
U2 - 10.1007/s11899-007-0012-4
DO - 10.1007/s11899-007-0012-4
M3 - Review article
C2 - 20425355
AN - SCOPUS:34248401176
SN - 1558-8211
VL - 2
SP - 83
EP - 88
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 2
ER -